Kestra Medical Technologies raised $196 million in an oversubscribed financing round co-led by Andera Partners, Ally Bridge Group, Longitude Capital and Omega Funds.

Kestra Medical Technologies, Inc. announced an oversubscribed $196 million funding round to support the expansion of their commercial organization and advance its mission of protecting at-risk patients with its modern Wearable Cardioverter Defibrillator (WCD). The round was co-led by Andera Partners, Ally Bridge Group, Longitude Capital and Omega Funds with participation from new investors, funds and accounts advised by T. Rowe Price Investment Management, Inc., Eventide Asset Management and Gilmartin Capital.